Johnson & Johnson’s medical technology unit and its health data company Verily have penned separate new deals with technology ...

Cancer health tech company Flatiron Health has unveiled six new blood cancer data sets that together comprise information ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Labcorp delivered mixed third-quarter results, with higher sales and raised profit | Labcorp reported solid third-quarter ...

Eli Lilly and computing giant Nvidia are teaming up to build a new supercomputer that the pair say will be the most powerful owned and operated by a pharmaceutical company.

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

Swiss CDMO Lonza is making a move to strengthen and speed up quality control testing with the purchase of French rapid ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Chinese life science contracting giant WuXi AppTec is taking another step to zero in on its core offerings by hiving off two China-based subsidiaries. | By separating itself from its China-based CRO ...

The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...